Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

Clinical trial NCT00633594 · COMPLETED

Trial details

NCT number: NCT00633594
Sponsor: SCRI Development Innovations, LLC
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Mantle Cell Lymphoma

Start date: 2008-06-01
Primary completion: 2015-04-01
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.